Literature DB >> 19294435

Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

C Walter1, M O Klein, A Pabst, B Al-Nawas, H Duschner, T Ziebart.   

Abstract

Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is a side effect primarily in patients receiving highly potent nitrogen-containing bisphosphonates. The exact etiopathology is unknown. In addition to reduced bone remodeling, there may also be an impact on soft tissues. The impact of nitrogen- (ibandronate, pamidronate, zoledronate) and non-nitrogen-containing bisphosphonates (clodronate) on human umbilicord vein endothelial cells (HUVEC), fibroblasts and osteogenic cells was analyzed employing cell viability testing and a scratch wound assay. The impact on the cell morphology of vital-stained osteogenic cells was investigated by cell visualization (confocal laser scanning microscopy). Pamidronate and zoledronate had the greatest negative impact on all cell lines, whereas the impact of ibandronate and clodronate was less distinct. The effect of clodronate on HUVEC and fibroblasts was particularly marginal. BP-ONJ could be a multifactorial event with multicellular impairments. This might result in altered wound healing. The increased impact of the highly potent bisphosphonates, particularly on non-bone cells, may explain the higher occurrence of BP-ONJ.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294435     DOI: 10.1007/s00784-009-0266-4

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  29 in total

Review 1.  Bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Eur Spine J       Date:  2003-09-16       Impact factor: 3.134

2.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Avvisati; Giordano Dicuonzo; Fabrizio Battistoni; Michele Gavasci; Alfredo Salerno; Vincenzo Denaro; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

3.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

4.  Varying Ti-6Al-4V surface roughness induces different early morphologic and molecular responses in MG63 osteoblast-like cells.

Authors:  H J Kim; S H Kim; M S Kim; E J Lee; H G Oh; W M Oh; S W Park; W J Kim; G J Lee; N G Choi; J T Koh; D B Dinh; R R Hardin; K Johnson; V L Sylvia; J P Schmitz; D D Dean
Journal:  J Biomed Mater Res A       Date:  2005-09-01       Impact factor: 4.396

5.  Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.

Authors:  D Aguiar Bujanda; U Bohn Sarmiento; M A Cabrera Suárez; J Aguiar Morales
Journal:  Ann Oncol       Date:  2006-11-02       Impact factor: 32.976

6.  Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

Authors:  Estee P Wang; Leonard B Kaban; Gordon J Strewler; Noopur Raje; Maria J Troulis
Journal:  J Oral Maxillofac Surg       Date:  2007-07       Impact factor: 1.895

7.  Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.

Authors:  A A Reszka; J Halasy-Nagy; G A Rodan
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

8.  Inhibition of oral mucosal cell wound healing by bisphosphonates.

Authors:  Regina Landesberg; Matthew Cozin; Serge Cremers; Victoria Woo; Stavroula Kousteni; Satrajit Sinha; LeeAnn Garrett-Sinha; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2008-05       Impact factor: 1.895

9.  Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.

Authors:  Amir H Montazeri; J Gordon Erskine; I Grant McQuaker
Journal:  Eur J Haematol       Date:  2007-07       Impact factor: 2.997

10.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Authors:  Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

View more
  50 in total

1.  Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.

Authors:  Joo-Young Ohe; Yong-Dae Kwon; Hyeon-Woo Lee
Journal:  Clin Oral Investig       Date:  2011-09-22       Impact factor: 3.573

Review 2.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

3.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

4.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

5.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

6.  Compressive force strengthened the pro-inflammatory effect of zoledronic acid on il-1ß stimulated human periodontal fibroblasts.

Authors:  Sarah Grimm; Ambili Mundethu; Judit Symmank; Christoph Hennig; Christian Walter; Elisabeth Reichardt; Heiner Wehrbein; Collin Jacobs
Journal:  Clin Oral Investig       Date:  2020-11-09       Impact factor: 3.573

7.  Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital.

Authors:  Zaid H Baqain; Faleh A Sawair; Zaid Tamimi; Nazzal Bsoul; Ghazi Al Edwan; Jamal K Almasad; Abdalla A Abbadi
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

8.  Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid.

Authors:  Fernanda Gonçalves Basso; Ana Paula Silveira Turrioni; Diana Gabiela Soares; Vanderlei Salvador Bagnato; Josimeri Hebling; Carlos Alberto de Souza Costa
Journal:  Support Care Cancer       Date:  2014-05-07       Impact factor: 3.603

9.  Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Authors:  Oliver Ristow; Carlos Gerngroß; Markus Schwaiger; Bettina Hohlweg-Majert; Melanie Ristow; Steffen Koerdt; Roswitha Schuster; Sven Otto; Christoph Pautke
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-28       Impact factor: 4.553

10.  Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study.

Authors:  Christian Walter; Christian Laux; Keyvan Sagheb
Journal:  Clin Oral Investig       Date:  2013-03-23       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.